Elmind Capital LP Makes New $8.18 Billion Investment in Krystal Biotech, Inc. $KRYS

Elmind Capital LP purchased a new stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) in the second quarter, according to its most recent 13F filing with the SEC. The fund purchased 22,000 shares of the company’s stock, valued at approximately $8,176,740,000. Krystal Biotech makes up 2.1% of Elmind Capital LP’s investment portfolio, making the stock its 15th largest position.

Several other institutional investors have also recently made changes to their positions in KRYS. Silvant Capital Management LLC purchased a new stake in shares of Krystal Biotech in the second quarter worth $30,000. Western Wealth Management LLC purchased a new position in Krystal Biotech during the first quarter worth about $34,000. Greenline Wealth Management LLC purchased a new position in Krystal Biotech during the fourth quarter worth about $34,000. Danske Bank A S bought a new position in Krystal Biotech in the 3rd quarter worth about $35,000. Finally, UMB Bank n.a. increased its stake in Krystal Biotech by 34.6% in the 4th quarter. UMB Bank n.a. now owns 144 shares of the company’s stock worth $36,000 after acquiring an additional 37 shares during the last quarter. Institutional investors own 86.29% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on KRYS shares. Jefferies Financial Group reiterated a “buy” rating and set a $474.00 price target on shares of Krystal Biotech in a research report on Monday, July 13th. Bank of America upped their price objective on shares of Krystal Biotech from $364.00 to $396.00 and gave the stock a “buy” rating in a research report on Tuesday, July 14th. TD Cowen raised their target price on shares of Krystal Biotech from $306.00 to $403.00 and gave the company a “buy” rating in a research note on Thursday, June 18th. Citigroup lifted their target price on shares of Krystal Biotech from $378.00 to $386.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. Finally, Chardan Capital raised shares of Krystal Biotech to a “strong-buy” rating in a research note on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Krystal Biotech has a consensus rating of “Moderate Buy” and an average target price of $365.40.

Krystal Biotech Trading Up 4.2%

KRYS opened at $356.19 on Wednesday. The stock has a 50-day moving average price of $348.02 and a 200-day moving average price of $302.59. Krystal Biotech, Inc. has a 12-month low of $136.73 and a 12-month high of $382.54. The stock has a market capitalization of $10.54 billion, a P/E ratio of 44.64 and a beta of 0.53.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, August 3rd. The company reported $1.79 EPS for the quarter, beating the consensus estimate of $1.70 by $0.09. The firm had revenue of $119.22 million for the quarter, compared to analyst estimates of $120.93 million. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%. On average, equities research analysts predict that Krystal Biotech, Inc. will post 7.68 EPS for the current year.

Insider Buying and Selling at Krystal Biotech

In other news, Director Dino A. Rossi sold 25,000 shares of the company’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $329.12, for a total value of $8,228,000.00. Following the completion of the sale, the director owned 50,000 shares of the company’s stock, valued at approximately $16,456,000. This represents a 33.33% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the transaction, the insider directly owned 1,378,155 shares in the company, valued at approximately $424,623,337.05. This represents a 1.78% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 51,000 shares of company stock worth $16,278,020 over the last ninety days. Insiders own 13.10% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.